(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 5.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Rigel Pharmaceuticals's revenue in 2023 is $132,368,000.On average, 4 Wall Street analysts forecast RIGL's revenue for 2023 to be $19,240,105,331, with the lowest RIGL revenue forecast at $18,540,709,254, and the highest RIGL revenue forecast at $19,581,695,187. On average, 4 Wall Street analysts forecast RIGL's revenue for 2024 to be $23,499,603,550, with the lowest RIGL revenue forecast at $21,105,161,535, and the highest RIGL revenue forecast at $26,469,290,555.
In 2025, RIGL is forecast to generate $27,095,451,441 in revenue, with the lowest revenue forecast at $23,327,849,589 and the highest revenue forecast at $29,117,963,306.